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Patients with chronic kidney disease (CKD) stage 4 or 5 have the option of kidney 
transplantation, hemodialysis (HD), peritoneal dialysis (PD), or conservative management.1 
National Kidney and Urologic Disease Information Clearinghouse reported that in 2007, 
there were 368, 544 U.S. residents with ESRD who were receiving dialysis, of whom 341, 264 
were undergoing HD.2 Quality of life and long-term survival of patients with CKD who are 
on HD depends on the successful placement of vascular access, as autogenous arteriovenous 
access, prosthetic arteriovenous access, or tunneled central venous catheter. DOQI 
guidelines are emphatic that autogenous arteriovenous access placement should be 
considered first, as it provides the optimal vascular access, followed by prosthetic grafts if 
autogenous arteriovenous access placement is not possible. There is a great deal of 
controversy regarding the choice of synthetic or biological material, as the guidelines 
suggest that it should be based on surgeon's experience and preference. The evidence to 
support the superiority of tapered versus uniform tubes, thick- versus thin- walled 
characteristics, elastic versus non-elastic arterial, stretch vs. standard PTFE, externally 
supported vs. unsupported grafts, is still evolving. 
An ideal vascular graft would have the following characteristics: 1) appropriate size to 
match host vessels, 2) mechanical strength, 3) low thrombogenicity/ complete 
endothelialization, 4) rapid/ complete healing, 5) ease of handling, 6) resistance to 
infection, 7) structural durability in face of repeated needle puncture, 8) low incidence of 
hyperplastic intimal changes and 9) low cost.3 
In this chapter, we will review the development of vascular grafts over the years and 
discuss the advantages of one over the other. 
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2. Prosthetic grafts for hemodialysis 
Although the first synthetic graft used for HD access in the United States was made of 
Dacron dating back to the early 1970s, unfavorable results and the availability of better 
prosthetic materials like expanded PTFE (ePTFE) forced its abandonment. In 1976, Dr. Baker 
presented the first results of ePTFE grafts in 72 HD patients. Since then ePTFE remains the 
graft of choice for vascular access.4 ePTFE is considered the material of choice due to the fact 
that it is readily accessible, ease of implantation, good medium term patency, and relatively 
low complication rates compared to other synthetic and biological materials.5 The medical 
community has made strenuous efforts to increase the use of autogenous arterıovenous 
access, prevalence has increased from 22% in 1995 to 57.7% in 2011. However, the use of 
synthetic grafts still remains significant (18.4% prevalence in 2011).6,7 
2.1 Indications for use of prosthetic grafts 
Autogenous arteriovenous access are clearly superior in terms of long term patency to grafts, 
but not feasible in many patients undergoing HD8. The indications for prosthetic grafts 
include: lack of suitable vessels particularly in elderly and diabetic patients, need for 
immediate cannulation and in children who cannot tolerate multiple painful venipunctures.5 
2.2 Complications associated with prosthetic grafts 
Graft failures are typically caused by stenosis (leading cause of graft failure) due to thrombosis 
and neointimal hyperplasia at site of anastamosis, as well as graft infection (contributes to 10-
15% of graft failure).9,10 Other less common complications of prosthetic accesses include; steal 
syndrome, seromas, aneurysm formation, central vein stenosis and bleeding.11 Thrombosis 
seems to occur soon after implantation due to technical problem, with a clot typically forming 
at the surface of the graft when it is first exposed to blood. The clot is formed initially of 
platelet aggregates, and then fibrin and thrombin is laid down via activation of the coagulation 
cascade. Platelet activity is generally most intense during the first 24 hours and subsides to a 
very low level after 1 week.9 Neointimal hyperplasia in prosthetic conduits can be attributed to 
upstream and downstream events. The upstream factors include; hemodynamic stress at the 
graft-vein anastamosis, compliance mismatch between the graft material and vein (more 
studies required to establish this factor), arterial injury at the time of graft placement, intrinsic 
properties of the synthetic graft itself (shown to attract macrophages which then secrete 
specific cytokines bFGF, PDGF, and VEGF), graft injury from dialysis needles, as well as the 
presence of uremia (causing endothelial dysfunction even prior to synthetic graft implant).12-14 
The downhill events are essentially a consequence of the upstream events. Pro-inflammatory 
cells release cytokines promoting the migration of smooth muscle cells and myofibroblasts 
from the adventitia media into the intimal layer, where they proliferate and cause lesions of 
neointimal hyperplasia.13 These stenotic lesions are usually treated by percutaneous 
angioplasty (PTA) or open patch angioplasty, which unfortunately, predisposes the patient to 
restenotic lesions due to endothelial and smooth muscle cell injury.15 
Infection is the second most common complication of synthetic grafts and can lead to further 
complications such subacute bacterial endocarditis, epidural or brain abscess.11 These 
complications can lead to graft failure in up to 35% of patients.16 Graft infections have an 
incidence rate as high as 2%, and are 4 times as prevalent in synthetic grafts when compared 
to autogenous veins.9 Common causative organisms are Staphylococcus aureus (26.32% of  
 
www.intechopen.com
 Current Status of Synthetic and Biological Grafts for Hemodialysis 287 
 
www.intechopen.com
 Hemodialysis - Different Aspects 288 
 
www.intechopen.com
 Current Status of Synthetic and Biological Grafts for Hemodialysis 289 
 
www.intechopen.com
 Hemodialysis - Different Aspects 290 
 
www.intechopen.com
 Current Status of Synthetic and Biological Grafts for Hemodialysis 291 
 
www.intechopen.com
 Hemodialysis - Different Aspects 292 
 
www.intechopen.com
 Current Status of Synthetic and Biological Grafts for Hemodialysis 293 
 
www.intechopen.com
 Hemodialysis - Different Aspects 294 
 
Abbreviations: polytetrafluoroethylene (PTFE), expanded polytetrafluoroethylene (ePTFE), carbon 
lined (CL), graft platelet accumulation index (GPAI), high porous (HP), tridodecylmethylammonium 
chloride (TDMAC), polycarbonate polyurethane (PU), per patient year (PPY), polyurethaneurea (PUU), 
polyurethane vascular graft (PVG), transposed brachio-basilic fistula (TBB), clot free survival (CFS), 
autogenous brachial vein-brachial artery access (ABBA), brachio-basilic arteriovenous fistula (BBAVF), 
Not available (N/ A) 
Table 1. Clinical trials of prosthetic grafts for hemodialysis. 
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infections cultured), methacillin resistant Staphylococcus aureus (21.05%), followed by 
Pseudomonas aeruginosa (5.26%).11 The largest number of infections occur when patients 
are going under routine dialysis (more than 50% of patients) and as a complication of 
chronic cannulation, rather than postoperative complications.11 Reducing Staphylococcus 
aureus carrier state in patients undergoing HD and improving antiseptic technique may 
reduce the rate of infections in grafts. 
2.3 Characteristics of PTFE grafts 
While PTFE is available in various configurations and is produced by various manufacturers, 
very few have proven to be more beneficial in improving patency in randomized clinical trials 
for long-term.1 
2.3.1 Effect of wall thickness 
In order to examine the effect of wall thickness on patency, Lenz et al.17 investigated both 
standard wall and thin wall configuration of PTFE. Although the incidence of complications 
and mortality did not statistically differ amongst the 2 groups, standard ePTFE had better 
patency rates. Studies comparing 2 manufacturers of ePTFE grafts: Gore-Tex® (W.L. Gore 
and Associates, Flagstaff, AZ) and Impra® (C. R. Bard Inc., Murray Hill, NJ) did not find 
any difference in the performance of 6-mm standard ePTFE grafts.18 19 
2.3.2 Effect of stretch characteristics 
In an attempt to reduce kinking of the graft in areas of angulation and to improve 
intraoperative handling, the graft was modified to stretch (Gore- Tex® Stretch). Tordoir et 
al. reported a cumulative primary patency rate of 59% in the stretch ePTFE group compared 
to 29% in standard ePTFE group at 1 year (p < 0.01). In addition, there were significantly 
fewer thrombotic events for the stretch ePTFE grafts as opposed to the standard ePTFE 
grafts (40%vs. 12%, p<0.001).20 Early cannulation of stretch ePTFE grafts was not found to 
increase peri-operative morbidity rates or decrease 12-month cumulative primary patency 
rates.21 In contrast, another study comparing the patency of early cannulation with late 
cannulation in Gore-Tex® stretch grafts showed that graft patency after thrombosis 
formation was significantly higher in the late cannulation group (p=0.0002).22 
2.3.3 Effect of ringed reinforcement 
Ring reinforced grafts were created to reduce kinking at the apex of loop grafts and decrease 
incidence of thrombosis associated with external compression. In a retrospective study in 
which 632 reinforced and non-reinforced PTFE grafts were compared for patency and 
complications, it was found that non-reinforced grafts had higher primary and secondary 
patency rates.23 
2.3.4 Effect of cuff or hood on venous ourflow 
One of the few modifications that improved patency rates in PTFE vascular grafts was 
placing a cuff or hood on the venous outflow. The main objective of placing a cuffed PTFE 
graft is to enlarge the outflow, and reduce mechanical sheer stress in order to reduce 
thrombotic occlusion caused by neointimal hyperplasia.1 In a computer simulated model, 
Venaflo® II (C. R. Bard Inc., Murray Hill, NJ), a flared-end ePTFE graft to simulate a vein  
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Abbreviations: bovine carotid artery heterograph (BCAH), polytetrafluoroethylene (PTFE), 
arteriovenous fistula (AVG), bovine mesenteric vein graft (BMVG), preserved saphenous vein (PSV), 
Endoscopic Vessel Harvesting System (EVHS), hemodialysis (HD), SynerGraft® (SG), polyurethaneurea 
(PUU), Not available (N/ A). 
Table 2. Clinical trials of biological conduits for hemodialysis 
www.intechopen.com
 Hemodialysis - Different Aspects 300 
cuff, showed measurable improvements in reducing wall shear stress gradient, wall shear 
stress angle gradient, and radial pressure gradient.25 Sorom et al.26found that Venaflo® II 
was associated with increased blood flow rates during HD and improved graft patency 
compared with ePTFE graft. Similarly, in a smaller study it was found that a flared-end 
ePTFE graft provided stable blood flow and satisfactory graft patency during 2 years of 
follow-up, even in high risk patients with a prior history of vascular access thrombosis.27 
However, a European study did not show improvement in patency rate despite a reduction 
in thrombotic occlusion and stenosis.24 
2.3.5 Effect of coating PTFE 
Another technique meant to improve PTFE graft has been coating the PTFE vascular grafts 
with carbon or heparin to prevent early graft failure and improve overall patency rates.28 In 
a canine model, Tsuchida et al. showed that the graft platelet accumulation index (GPAI) 
was significantly (p<0.05) lower in the carbon lined PTFE group when compared to the 
control PTFE group.29 They concluded that carbon lining decreases platelet accumulation on 
PTFE grafts. Propaten®, ePTFE with bioactive heparin covalently  bound to it (W.L. Gore 
and Associates) has also been shown to be effective in improving graft patency. It is the only 
vascular graft of its kind approved for HD access on the market. Davidson et al. 30 found 
20% improved primary graft patency of about 80% at one year when comparing Propaten® 
to standard ePTFE. In order to diminish the risk of neointimal hyperplasia. Cagiannos et 
al.31 studied the effects of coating an ePTFE graft with rapamycin in a porcine model. They 
showed that the rapamycin coated grafts significantly (P <0.0001) lowered cross sectional 
narrowing in the outflow graft when compared to non-coated grafts; as well as no evidence 
of medial necrosis or aneurysmal degeneration. After a four week observation period, 
coated grafts showed features of diminished neointimal hyperplasia compared to untreated 
ePTFE grafts. Researchers have also analyzed the effect of a bioabsorbable vascular wrap 
mesh containing paclitaxel on neointimal hyperplasia in a sheep model. Paclitaxel coated 
mesh significantly reduced neointimal hyperplasia and neointimal capillary density without 
toxicity to adjacent vessels.32 
2.3.6 Self-sealing grafts 
K/ DOQI recommends that PTFE grafts should not be routinely used until at least 2 weeks 
after placement and not until swelling has subsided so that palpation of the course of the 
graft can be performed. This time is needed for tissue-to-graft incorporation, reducing peri 
graft hematoma.1 Due to this complication, newer 惇self-sealing敦 grafts have been designed 
that can be cannulated sooner.11 Vectra® vascular grafts (C. R. Bard Inc., Murray Hill, NJ) 
made of a proprietary blend of segmented polyetherurethaneurea and a siloxane containing 
a surface-modifying additive (SMA), were designed to provide early cannulation, reducing 
the need for temporary central venous catheters to provide access until the graft matures. In 
a study of 76 patients, in which Vectra® grafts were compared to transposed brachio-basilic 
vein (TBB) autogenous access, Kakkos et al.33 found that aggressive graft surveillance and 
endovascular treatment methods resulted in equivalent long-term secondary patency rates. 
The advantage of earlier use of Vectra® graft must be balanced against the need for more 
frequent secondary interventions and the risk of graft infection. In a single center study, Jefic 
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et al. obtained 81% (108 of 133 grafts) cannulation rate within 4 days of Polyurethane (PU) 
[Thoratec® Vascular Access Graft] graft placement in which none of the recipients required 
a temporary catheter. A shorter mean bleeding time after withdrawal of dialysis needle was 
also acquired in the PU graft group (4.0 minutes vs. 9.2 minutes in ePTFE group).34 
Similarly, Glickman et al. showed that PU grafts had achieved better hemostasis at 
cannulation sites compared to ePTFE sites when the two were compared at 5 minutes or less 
after dialysis (P<0.0001). Also, they showed that 53.9% of all PU grafts were cannulated 
before 9 days vs. none of the ePTFE grafts (P<0.001).35 In the HIV- positive ESRD patient 
population, reduction of temporary catheter use and prevention of infection is critical. A 
study of 30 consecutive HIV positive patients receiving Vectra® graft implantation showed 
a lower infection rate (10% vs. 45%) than published reports of infection in PTFE grafts. It 
was concluded that the unique self-sealing property of the Vectra® grafts reduced the 
development of perigraft hematoma and may have accounted for decreased infection.36 
3. Biological conduits for hemodialysis 
Biological graft materials tend to have less intimal hyperplasia at the venous anastamosis, 
reduced tendency to thrombose, and a lower risk of infection when compared to PTFE.11 
Butler et al. compared bovine heterographs to PTFE and found that the synthetic graft had 
significantly fewer late thromboses, increased resistance to infection, easier to repair and 
had comparable longevity.37 Anderson et al. found that bovine heterographs required twice 
as many revisions per dialysis month to maintain patency.38 
SynerGraft® 100 (SG100 [CryoLife Inc., Atlanta, GA]) is a modified bovine ureter graft with 
some similarities to synthetic graft (similar internal diameter and strong tissue matrix). This 
graft has been processed to remove xenograft cells while maintaining a collagen matrix that 
is not chemically cross-linked by aldehydes allowing re-population by autologous cells. 
Matsuura et al. reported a primary patency rate of 72.6% and 58.6% for SG 100 vs. 57.4% and 
54.7% for the ePTFE grafts at 6 months and 12 months, respectively. SG 100 graft showed 
fibroblast cell migration and proliferation with incorporation into the surrounding 
subcutaneous tissue after 10 weeks, and procollagen synthesis demonstrated at 24 weeks; 
while the ePTFE graft had no evidence of cellular ingrowth.39 In a study of 23 patients 
receiving SG 100 grafts, Darby et al. found that the bovine ureter graft was a stable vascular 
access conduit, providing a suitable graft alternative when autologous vein was not 
available. Their study showed 29% primary, 45% primary assisted, and 81% secondary 
patency rates at 1 year, with only a 5% infection rate.40 On the other hand, Chemla et al. 
found that both grafts were adequate conduits for HD, the anticipated advantages for SG 
100 were not seen in either patency or stability.41 
4. Future developments in prosthetic and biological conduits for 
hemodialysis 
The use of pharmacological agents may hold the promise of long-term graft patency. 
Treatment with 200 mg of dipyridamole and 25 mg of aspirin twice daily resulted in 
significant improvement of patency rates while adverse effects in both the treatment and 
placebo groups remained the same.45 Other agents, such as fish oil and anticoagulants have 
also been tried with limited success (table 4). 
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Abbreviations: expanded polytetrafluoroethylene (ePTFE), Not available (N/ A) 
Table 3. Clinical trials of experimental conduits for hemodialysis 
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Abbreviations: expanded polytetrafluoroethylene (ePTFE), polytetrafluoroethylene (PTFE), Not 
available (N/ A). 
Table 4. Effects of various medications on vascular access grafts 
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In an approach of reducing neointimal hyperplasia by decreasing mechanical sheer stress, a 
new double channel (Bi-Flow) graft was designed. These grafts showed laminar flow and 
lower levels of turbulence, leading to lower risk of stenosis.46 
5. Conclusions 
Prosthetic grafts should be reserved for situations where autogenous vein is not available to 
perform an access. The most commonly used prosthetic graft is e-PTFE based. Newer 
advances in medication bonding to decrease thrombosis and formation of intimal 
hyperplasia may be promising. In addition, various graft characteristics such as flared-end 
and stretch may provide better patency. Biologic grafts are being tested; however, at this 
point data are lacking to show superiority over prosthetic grafts. This area is a fertile ground 
for randomized clinical trials in the search for a man made or biologic graft that would equal 
autogenous vein in patency and complication rates. 
6. Abbreviations 
Chronic kidney disease (CKD), hemodialysis (HD), peritoneal dialysis (PD), arteriovenous 
fistula (AVF), polytetrafluoroethylene (PTFE), expanded PTFE (ePTFE), transposed 
brachialbasilic vein (TBB), percutaneous angioplasty (PTA) 
7. Definitions 
Primary Patency: Interval of time from access placement to any intervention necessary 
tomaintain patency of access. Assisted Primary Patency: Interval of time from access 
placement to time of intervention necessary to maintain the functionality of the access. 
Secondary Patency: Interval of time from access placement to access abandonment including 
intervening surgical or endovascular manipulations 
8. Manufacturer and graft 
Graft Graft Material Manufacturer 
Artegraft® Bovine Carotid Artery Heterograft 
Artegraft Inc., New 
Brunswick, NJ 
Atrium Adventa™ VXT Reinforced ePTFE 
Atrium Medical Corp., 
Hudson, NH 
Boston Scientific  ePTFE 
Boston Scientific Corp., 
Natick, MA 
Carboflo® Carbon impregnated ePTFE 
C.R. Bard Inc., Murry 
Hill, NJ 
CryoVein® Cryopreserved femoral vein 
CryoLife Inc., Atlanta, 
GA 
Flixene™ Trilaminate membrane 
Atrium Medical Corp., 
Hudson, NH 
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Graft Graft Material Manufacturer 
Gore-Tex® ePTFE 
W.L. Gore and 
Associates, Flagstaff, AZ 
Gore-Tex® Intering® 
graft 
reinforced ePTFE with radial support 
W.L. Gore and 
Associates, Flagstaff, AZ 
Gore-Tex® stretch graft Stretch ePTFE 
W.L. Gore and 
Associates, Flagstaff, AZ 
Gore-Tex® stretch graft 
with removable rings 
Stretch ePTFE with removable rings 
W.L. Gore and 
Associates, Flagstaff, AZ 
Impra® ePTFE 
C.R. Bard Inc., Murry 
Hill, NJ 
Dardik Biograft™ Modified human umbilical vein  
Meadox Medicals Inc., 
Oakland, NJ. 
ProCol® Bovine mesenteric vein heterograph 
Hancock Jaffe 
Laboratories Inc., Irvine, 
CA 
Propaten® 
Bioactive heparin convalently bound to 
ePTFE 
W.L. Gore and 
Associates, Flagstaff, AZ. 
SynerGraft® 100 Bovine Ureter Graft 








Self-sealing polycarbonate urethane 
graft 
Lemaitre Vascular Inc., 
Burlington, MA 
Vascutek® Self-sealing ePTFE 
Tarumo Interventional 
Systems, Somerset, NJ 
Vectra® 
Proprietary blend of segmented 
polyetherurethaneurea and a siloxane 
C.R. Bard Inc., Murry 
Hill, NJ 
Venaflo®  II Cuffed ePTFE 
C.R. Bard Inc., Murry 
Hill, NJ 
9. Disclaimer 
The views expressed in this article are those of the authors and do not necessarily reflect the 
official policy of the Department of Army, the Department of Defense, or the US 
government. 
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